Original Article
Artemisinin Resistance in Plasmodium falciparum Malaria
N Engl J Med 2009; 361:455-467July 30, 2009
- Abstract
Background
Artemisinin-based combination therapies are the recommended first-line treatments of falciparum malaria in all countries with endemic disease. There are recent concerns that the efficacy of such therapies has declined on the Thai–Cambodian border, historically a site of emerging antimalarial-drug resistance.
Methods
In two open-label, randomized trials, we compared the efficacies of two treatments for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, northwestern Thailand: oral artesunate given at a dose of 2 mg per kilogram of body weight per day, for 7 days, and artesunate given at a dose of 4 mg per kilogram per day, for 3 days, followed by mefloquine at two doses totaling 25 mg per kilogram. We assessed in vitro and in vivo Plasmodium falciparum susceptibility, artesunate pharmacokinetics, and molecular markers of resistance.
Results
We studied 40 patients in each of the two locations. The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001). Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate–mefloquine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), respectively, in Wang Pha (P=0.31). These markedly different parasitologic responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative molecular correlates of P. falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco–endoplasmic reticulum calcium ATPase6 [PfSERCA]). Adverse events were mild and did not differ significantly between the two treatment groups.
Conclusions
P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand. Resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing. Containment measures are urgently needed. (ClinicalTrials.gov number, NCT00493363, and Current Controlled Trials number, ISRCTN64835265.)
Media in This Article
Figure 1
Enrollment, Randomization, and Follow-up of the Patients in the Two Studies.Figure 2
Parasite Clearance Curves.Article Activity
- Article
Artemisinins are established antimalarial agents with an excellent safety profile.1 Artemisinin-based combination therapies are now recommended by the World Health Organization (WHO) as first-line treatment of uncomplicated falciparum malaria in all areas in which malaria is endemic.2 Replacing ineffective, failing treatments (chloroquine and sulfadoxine–pyrimethamine) with artemisinin-based combination therapies has reduced the morbidity and mortality associated with malaria.3-5 Parenteral artesunate is replacing quinine for the treatment of severe malaria.6 Recently, there have been signs that the efficacy of artemisinin-based combination therapy and artesunate monotherapy have declined in western Cambodia.7-10 Artemisinin resistance would be disastrous for global malaria control. To characterize treatment responses to artemisinin derivatives and provide evidence for planning containment-measure strategies, WHO and the National Malaria Control Programmes of Cambodia and Thailand established a multipartite task force. The trials reported here were conducted as part of this initiative.
Methods
Study Design
We conducted two open-label, randomized, clinical, parasitologic, and pharmacokinetic studies to compare therapeutic responses to artesunate in Pailin, western Cambodia, where artemisinins have been used for more than 30 years, and at the northwestern Thai–Burmese border, a region where artemisinin-based combination therapies were first deployed11 in 1994 and remain highly effective.5 The study was monitored externally. Approval for the study design was obtained from the Ministry of Health in Cambodia, the Ethics Committee of the Faculty of Tropical Medicine of Mahidol University in Thailand, the Oxford Tropical Medicine Ethical Committee, the WHO Research Ethics Review Committee, and the Technical Review Group of the WHO Western Pacific Regional Office.
Study Sites and Patients
The studies were conducted in Pailin Referral Hospital in western Cambodia and in the Shoklo Malaria Research Unit (SMRU) clinic in Wang Pha, Tak Province, northwestern Thailand. Malaria transmission is low and seasonal in both sites.12 In Pailin, children over 5 years of age and nonpregnant adults with uncomplicated falciparum malaria (parasite density, ≥10,000 per cubic millimeter of blood at the time of screening) were enrolled if written informed consent had been obtained from the patient or, if a child, from a parent or guardian. The study in Wang Pha, Thailand, started later, but the Ethics Committee of the Faculty of Tropical Medicine of Mahidol University did not approve the enrollment of children, so only nonpregnant adults and children at least 16 years of age were enrolled, after written informed consent had been provided by the patient or, if a child, by a parent or guardian. Patients with severe disease,2 coinfection, infection with other malaria species, antimalarial-drug use within 48 hours before enrollment, or known allergies to artesunate or mefloquine were excluded.
Drug Therapy
Patients were randomly assigned, in blocks of 10, to receive either artesunate (Guilin Pharmaceutical, with repacking and quality control by Sanofi-Synthelabo for distribution in Cambodia and by Atlantic for distribution in Thailand) or artesunate plus mefloquine (Medochemie for Cambodia and MephaPharma for Thailand). The artesunate monotherapy was administered as 2 mg per kilogram of body weight per day, orally, for 7 days. The artesunate–mefloquine therapy was administered as artesunate at a dose of 4 mg per kilogram per day, orally, for 3 days, plus mefloquine at a dose of 15 mg per kilogram on day 3 and 10 mg per kilogram on day 4.
Opaque envelopes contained the unique study numbers of the patients, with the numbers referring to numbered allocated antimalarial treatments stored in an opaque, hard-cover box. Drug administration was directly observed. If vomiting occurred within 30 minutes after administration, the full dose was repeated; if it occurred between 30 and 60 minutes after administration, half the dose was given. The use of antibiotics with antimalarial activity was avoided. All patients were hospitalized for 7 days.
Clinical Procedures
A full clinical history was obtained on admission to the hospital, and a physical examination and blood collection were carried out. Tympanic temperature was recorded every 6 hours. Fever clearance times were defined as the time to the first temperature reading of less than 37.5°C and the time to the start of the first 24-hour period during which the temperature remained below 37.5°C. Adverse events were recorded on a standard form. Parasite asexual stages and gametocyte counts were determined at 0, 4, 8, and 12 hours and then every 6 hours until two consecutive slides were free of asexual parasites. The parasite clearance time was defined as the time from the start of treatment until the first negative blood smear. Parasite-reduction ratios were calculated as 100 minus the percentage reduction from the baseline level.
Follow-up Evaluations
Patients were assessed weekly until day 63 after enrollment and were advised to return if they felt unwell. Blood specimens were collected on enrollment and at the time of any recurrent parasitemia, for purposes of parasite genotyping. DNA extraction and purification were performed with the use of a standardized kit (QIAamp DNA Mini Kit, Qiagen). Amplification and analysis were performed as described previously.13 Polymorphisms in genes encoding the surface proteins of the Plasmodium falciparum merozoite (MSP-1 and MSP-2) and the glutamate-rich protein (GLURP) were compared between samples obtained before and after treatment to distinguish reinfection from recrudescence.14
Recurrent P. falciparum infection was treated in the artesunate-monotherapy group with artesunate at a dose of 4 mg per kilogram per day, and in the artesunate–mefloquine group with artesunate at a dose of 6 mg per kilogram per day, combined with doxycycline at a dose of 3.5 mg per kilogram per day in patients 8 years of age or older or clindamycin at a dose of 10 mg per kilogram twice a day in younger children. All these regimens were 7 days in duration.
Pharmacokinetics of Artesunate and Dihydroartemisinin
Venous-blood specimens were obtained at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 hours after the first artesunate dose. In Pailin, the samples were collected on ice in prechilled fluoride–oxalate tubes. After methodologic investigations,15 the tubes were changed to prechilled lithium–heparin tubes for the Thailand study. Samples were centrifuged at 4°C and stored in liquid nitrogen until analysis. Plasma concentrations of artesunate and dihydroartemisinin (the active metabolite of artesunate) were measured by means of high-throughput liquid chromatography–tandem mass spectrometry after solid-phase extraction.16 Artesunate and dihydroartemisinin labeled with a stable isotope were used as internal standards. The coefficients of variation for all quality-control samples were less than 5% at all drug concentrations. Pharmacokinetics were characterized through noncompartmental analysis, with the use of WinNonlin software, version 5.0 (Pharsight). Artesunate and dihydroartemisinin concentrations at the Cambodian site were multiplied by 1.09 to adjust for the different anticoagulants used at the Thai site.15 We report the observed maximum plasma concentrations of artesunate and dihydroartemisinin and the observed times to the maximum concentration.
In Vitro Testing of Antimalarial-Drug Susceptibility
In vitro testing of drug sensitivity was performed in parasites freshly obtained from the study patients at the Institute Pasteur laboratories (Phnom Penh, Cambodia) and at SMRU (Mae Sot, Thailand) by means of the standard 48-hour 3H-hypoxanthine uptake inhibition method.17 The laboratory-adapted strain 3D7 was used as a reference. The 50% inhibitory concentration was determined with the use of log-probit approximation, to fit the concentration–inhibition data.
Molecular Markers of Antimalarial-Drug Resistance
Copy numbers of the P. falciparum multidrug-resistance gene PfMDR1 were assessed by means of a real-time polymerase-chain-reaction (PCR) assay (Taqman) involving previously described primers and probes.18 The P. falciparum 3D7 strain was used as an external control, and the gene encoding β-tubulin as an internal control. Polymorphisms in PfMDR1 and the gene encoding P. falciparum chloroquine resistance transporter (PfCRT) were assessed with the use of a PCR restriction-fragment-length–polymorphism assay or direct gene sequencing. The gene encoding sarco–endoplasmic reticulum calcium ATPase6 (PfSERCA) was amplified by means of PCR and then directly sequenced. Analysis was performed with Bioedit software.
Statistical Analysis
We calculated that we would need to enroll 40 patients at each of the two study sites to allow for the detection of a difference between the proportions of patients in whom parasitemia persists after 72 hours after the start of treatment in Wang Pha, Thailand (4%, on the basis of historical data), and Pailin, Cambodia (expected to be at least 25%), with a significance level of 5% and a statistical power of 80%. Data were analyzed by means of Student's t-test, the chi-square test, or the Mann–Whitney U test, as appropriate. Parasite clearance times, fever clearance times, and the duration of gametocyte carriage were assessed by means of survival analysis with the use of the Kaplan–Meier method and the Wilcoxon–Breslow–Gehan test. Rates of gametocyte carriage were calculated as the total carriage time per total person-weeks of follow-up. To adjust for the higher parasite load at baseline in Pailin, the analysis was stratified according to the log10-normalized parasite load, with strata of less than 5.00 and 5.00 or more. Multivariate regression was also performed, with parasite clearance time as the dependent variable and study site and baseline parasite density as independent variables. Linear regression modeling was performed with the use of serial log parasite counts to estimate the times to clearance of 50% and 90% of the parasite load for each patient. All analyses were performed with the use of Stata software, version 10 (StataCorp).
Results
Between June 2007 and May 2008, a total of 80 patients were enrolled: 40 in Pailin, of whom 11 (28%) were under 16 years of age, and 40 in Wang Pha, where children were not enrolled (Figure 1Figure 1
Enrollment, Randomization, and Follow-up of the Patients in the Two Studies. and Table 1Table 1
Baseline Characteristics of the Study Patients, According to Location., and Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). The number of days of fever before enrollment was similar in Pailin (median, 3 days; range, 1.5 to 8) and in Wang Pha (median, 2 days; range, 1 to 6) (P=0.21).Parasitologic and Clinical Responses
Parasite clearance was markedly slower in Pailin (Table 2Table 2
Clinical and Parasitologic Responses in the Study Patients, According to Location.), with a median parasite clearance time for both Pailin treatment groups combined of 84 hours (interquartile range, 60 to 96), as compared with 48 hours (interquartile range, 36 to 66) in both Wang Pha groups (P<0.001). After the start of treatment in Pailin, 73% of patients had parasitemia at 48 hours, 55% at 72 hours, and 20% at 96 hours; the corresponding percentages in Wang Pha were 45%, 8%, and 3% (P<0.001). In Pailin, the parasite density at baseline was similar in children under 16 years of age (geometric mean, 50,046 per cubic millimeter; 95% confidence interval [CI], 22,767 to 110,007) and in children at least 16 years of age and adults (geometric mean, 71,366 per cubic millimeter; 95% CI, 49,614 to 102,654) (P=0.33). In Pailin, the median parasite clearance time among the 11 children was 78 hours (interquartile range, 60 to 96), as compared with 84 hours (interquartile range, 66 to 96) among the 29 adults and children at least 16 years of age (P=0.67). To assess whether exclusion of children from the Wang Pha, Thailand, study influenced the results, data from the Cambodian children were excluded from the analysis; the difference in parasite clearance times between the two study sites remained significant (P<0.001) (Table S2 in the Supplementary Appendix). We also compared the parasite clearance times as calculated on the basis of daily parasite counts in 3264 patients (1996 adults and children at least 16 years of age, and 1268 children under 16 years of age) in the Thailand study area between 1995 and 2007, as well as the times as calculated on the basis of counts every 6 hours in 1214 patients with hyperparasitemia (449 adults and children at least 16 years of age, and 765 children under 16 years of age) who were treated with artesunate-containing regimens. After adjustment for parasitemia, study location, and year of admission, there was no significant difference for children under 16 years of age as compared with adults and children at least 16 years of age in parasite clearance times (P>0.20 for all comparisons).The difference in parasite clearance times also remained significant when the analysis was stratified according to the log10-normalized parasite density on admission (P=0.008). Further analysis involving linear regression, adjusted for baseline parasite density, showed that site was a significant independent predictor of the time to parasite clearance, whether children were included in the model (coefficient, 18.1; 95% CI, 8.9 to 27.2; P<0.001) or excluded from the model (coefficient, 18.7; 95% CI, 8.0 to 29.4; P=0.001). Other measures of parasite reduction that are less dependent on the initial parasite load, including the parasite-reduction ratios after 24 and 48 hours and the slope of the log10-normalized parasite clearance over time, were also markedly different between the study sites (Table 2 and Figure 2Figure 2
Parasite Clearance Curves.).In Pailin, there was no evident dose–response relationship for artesunate: the median parasite clearance time was 84 hours (interquartile range, 54 to 96) for the dose of 2 mg per kilogram and 72 hours (interquartile range, 60 to 96) for the dose of 4 mg per kilogram (P=0.61). In contrast, in Wang Pha, patients treated with artesunate at a dose of 4 mg per kilogram had faster parasite clearance (median, 48 hours; interquartile range, 30 to 54) than those treated with artesunate at a dose of 2 mg per kilogram (median, 54; interquartile range, 42 to 72) (P=0.02) (Table 2).
Fever clearance times did not differ significantly between the two study sites (Table 2). Early treatment failure, defined as parasitemia and fever persisting for more than 3 days (≥72 hours) after the start of treatment,2 occurred in 3 of the 40 patients (8%) in Pailin, as compared with none in Wang Pha (P=0.20). In the artesunate-monotherapy group, late parasitologic failure (defined as PCR-confirmed recrudescence of P. falciparum infection >7 days after the start of treatment)2 occurred in 6 of the 20 patients (30%) in Pailin after a median of 28 days (range, 21 to 35) and in 2 of the 20 patients (10%) in Wang Pha, after 21 days for both patients. In the artesunate–mefloquine group, there were no occurrences of early treatment failure, and late parasitologic failure occurred in 1 of the 20 patients (5%) at each site, after 49 days in Pailin and 34 days in Wang Pha. Reinfection was more common in Wang Pha than in Pailin (P=0.001) (Table 2). Recurrent infection with P. vivax was common at both study sites. The median duration of patent gametocytemia per person-weeks of follow-up was 0.06 weeks (95% CI, 0.05 to 0.07) in Wang Pha and 0.07 weeks (95% CI, 0.06 to 0.08) in Pailin (P=0.13). The duration of gametocyte carriage in patients who had gametocytemia at any time also did not differ significantly between the sites (Table 2).
The number of patients reporting an adverse event did not differ significantly between the two treatment groups (Table S3 in the Supplementary Appendix). Dizziness, joint pain, muscle pain, and sleepiness were more common in Wang Pha, whereas nausea, abdominal pain, and fatigue were reported more frequently in Pailin. No serious adverse events were observed.
Pharmacokinetics
Body-weight–normalized doses of the study drugs were similar at the two study sites. Plasma-concentration profiles of artesunate and dihydroartemisinin, and the pharmacokinetic variables derived from them, were generally similar at the two sites, although the areas under the concentration–time curves were slightly greater in Pailin (Table 3Table 3
Results of Noncompartmental Analysis of First-Dose Pharmacokinetics, According to Study Drug.). There was no significant correlation between the maximum concentration of artesunate or dihydroartemisinin, or the area under the concentration–time curve, and measures of parasite clearance (parasite clearance time and parasite-reduction ratios after 24 and 48 hours) or the risk of treatment failure (Figure S1 in the Supplementary Appendix). Exclusion of children from the analysis did not affect these findings.In Vitro Sensitivity Testing
Reliable fitting of the hypoxanthine-uptake curves for artesunate and dihydroartemisinin was possible for 18 of the 40 patients for both drugs in Pailin and 32 of 40 patients and 30 of 40 patients, respectively, in Wang Pha. The median 50% inhibitory concentration of artesunate in Pailin was 1.9 nM (interquartile range, 1.3 to 3.4), as compared with 3.2 nM (interquartile range, 1.7 to 4.1) in Wang Pha (P=0.07) and 2.7 nM for the reference strain 3D7. The median 50% inhibitory concentration of dihydroartemisinin in Pailin was 2.3 nM (interquartile range, 1.1 to 3.2), as compared with 1.5 nM (interquartile range, 0.7 to 2.2) in Wang Pha (P=0.04) and 2.3 nM for the reference 3D7 (Figure 3Figure 3
The 50% Inhibitory Concentration (IC50) for Plasmodium falciparum, According to Antimalarial Drug.). There were no significant correlations between the 50% inhibitory concentration of artesunate or dihydroartemisinin and the parasite clearance times in Pailin (artesunate: r=0.07, P=0.70; dihydroartemisinin: r=0.19, P=0.33) or Wang Pha (artesunate: r=0.20, P=0.44; dihydroartemisinin: r=0.28, P=0.23). The 50% inhibitory concentrations of mefloquine and chloroquine did not differ significantly between the two study sites (Figure 3).Molecular Markers of Resistance
In Pailin, 38 of 40 patients (95%) had parasites that contained single copies of PfMDR1, and the 2 remaining patients (5%) had two copies, both associated with 50% inhibitory concentrations of mefloquine exceeding 150 nM. In Wang Pha, 18 of the 40 patients (45%) had isolates that contained multiple copies of PfMDR1 (median, 2; range, 1 to 3; P<0.001). We did not detect any point mutations in the PfMDR1 gene at positions N86Y, S1034C, N1042D, and D1246Y, but the mutant codon Y184F was found in isolates from 32 of the 40 patients (80%) in Pailin and 12 of the 40 patients (30%) in Wang Pha. All parasites had the K76T mutation in the PfCRT gene. Full-length sequencing of the PfSERCA gene revealed sporadic point mutations noted as I89T (in isolates from 5 of 50 patients), N465S (in isolates from 7 of 44 patients), and E847K (in isolates from 1 of 45 patients), with similar frequencies at the two study sites. The number of insertion–deletion mutations of T-A repeats located in the intron region of the gene (nt3621-3671) varied among parasites (range, 10 to 19) but did not differ between the two sites. The PfSERCA L263E and S769 N polymorphisms, proposed to confer artemisinin resistance, were not detected.
Discussion
Our study shows that P. falciparum parasites from patients in Pailin, western Cambodia, had significantly reduced in vivo susceptibility to artesunate, as compared with parasites from northwestern Thailand — or indeed, apparently, anywhere else in the world. Artesunate resistance was characterized by a markedly prolonged time to parasite clearance, with relatively little heterogeneity among patients. These reduced parasitologic responses could not be explained by pharmacokinetic or other host factors.
The principal pharmacodynamic advantage of using artemisinins rather than other antimalarial drugs is that they accelerate parasite clearance1 by clearing young, circulating, ring-stage parasites and preventing the further maturation and sequestration of these parasites.19,20 This effect accounts for the rapidity of the therapeutic response, its lifesaving benefit in patients with severe malaria, and the notable gametocytocidal activity of the drugs. A few cases of reduced efficacy of artemisinin-based combination therapy have been reported previously. Most of these cases can be explained by the counterfeit nature of the drugs tested.21 In 2002–2003, decreased in vitro sensitivity of P. falciparum to artemether was reported in French Guiana (but not in Cambodia) and was associated with the S769N mutation in the PfSERCA gene.22,23 There were no clinical correlates. In our study, there was no consistent pattern of PfSERCA mutations, despite clear evidence of in vivo artesunate resistance.
Monitoring in western Cambodia has shown a decline in the efficacy of artemisinin-based combination therapy in recent years, but the relative contributions of resistance to artemisinin, the partner drug, and other factors have been unclear.7-10,24 In a recent Cambodian study, increased numbers of copies of the PfMDR1 gene, a well-established cause of mefloquine resistance,18 was associated with high failure rates with artesunate–mefloquine therapy.7,25 In the current study, despite artesunate resistance, the efficacy of artesunate–mefloquine use was excellent in Pailin (63-day cure rate, 95%), presumably because 95% of parasite isolates had a single PfMDR1 copy. PfMDR1 amplification also causes a small decrease in artemisinin susceptibility,18 but neither this nor any other molecular markers of antimalarial-drug resistance that we evaluated could explain the resistance to artesunate in Pailin.
There was an unexpected discrepancy between the slow clinical and parasitologic responses in Pailin and the relatively normal in vitro susceptibility. The discrepancy can be explained by the reduced susceptibility of the young, ring-form parasites as compared with the more mature trophozoites and schizonts. Currently available in vitro susceptibility tests assess drug exposure over the entire parasite cycle; therefore, the results would be relatively unaffected if only part of the cycle were affected by the mechanism underlying the resistance. Previous studies have not indicated significant differences in parasitologic responses within the dose range that we evaluated (2 to 4 mg per kilogram per day).26 A concentration–effect relationship was evident in Wang Pha but not in Pailin, suggesting that a small shift to the right along the dose–response curve may also have occurred at the Thai–Burmese border.27
Chloroquine and sulfadoxine–pyrimethamine resistance in P. falciparum emerged in the late 1950s and 1960s on the Thai–Cambodian border and spread across Asia and then Africa, contributing to millions of deaths from malaria.28,29 Artemisinins have been available as monotherapies in western Cambodia for more than 30 years, in a variety of forms and doses, whereas in most countries (other than China, where they were discovered), they have been a relatively recent introduction.1 Despite the early implementation of an active malaria-control program by the Ministry of Health of Cambodia, including the introduction of artemisinin-based combination therapies in 2001, a recent survey showed that 78% of artemisinin use in western Cambodia consisted of monotherapy provided through the private sector.30 The extended period of often-suboptimal use, and the genetic background of parasites from this region,31 might have contributed to the emergence and subsequent spread of these new artemisinin-resistant parasites in western Cambodia. In contrast, artemisinin derivatives have been used almost exclusively in combination with mefloquine on the Thai–Burmese border, where parasitologic responses to artemisinins remain good, even after 15 years of intensive use.27 Measures for containment are now urgently needed to limit the spread of these parasites from western Cambodia and to prevent a major threat to current plans for eliminating malaria.
Supported by grants from the Wellcome Trust of Great Britain (Major Overseas Programme–Thailand Unit Core Grant) and the Li Ka Shing Foundation (B9RMXT0-2) and by the WHO through grants from the Bill and Melinda Gates Foundation (48821) and the U.S. Agency for International Development (umbrella grant AAG-G-00-99-00005).
No potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0808859) was updated on October 21, 2009, at NEJM.org.
We thank the patients for their participation; all staff members of the Pailin Referral Hospital and the SMRU clinic for their dedicated care for the patients and assistance in the study; Tim Anderson for help with the in vitro sensitivity testing; the Village Malaria Workers in Pailin for their collaboration; and Vasee Moorthy, Golam Kibria, Mark Fukuda, and George Watt for help in executing and organizing the trial in Pailin.
Source Information
From the Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok (A.M.D., F.N., D.D., J.T., W.H., S.J.L., K.S., M.I., K.C., T.H., S.Y., P.S., N.P.J.D., N.L., N.J.W.); Shoklo Malaria Research Unit, Mae Sot (F.N., A.P.P., K.M.L.); and Family Health International, Bangkok (S.S.A.) — all in Thailand; the Centre for Tropical Medicine, Churchill Hospital, Oxford, United Kingdom (A.M.D., F.N., J.T., S.J.L., N.P.J.D., N.L., N.J.W.); the National Center for Parasitology, Entomology, and Malaria Control (P.Y., D.S.); and Institut Pasteur du Cambodge (F.A., P.L.) — both in Phnom Penh, Cambodia; and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Address reprint requests to Dr. Dondorp at the Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd., Bangkok 10400, Thailand, or at arjen@tropmedres.ac.
- References
References
1
White NJ . Qinghaosu (artemisinin): the price of success. Science 2008;320:330-334
CrossRef | Web of Science | Medline2
WHO guidelines for the treatment of malaria. Geneva: World Health Organization, 2006.
3
Barnes KI ,Durrheim DN ,Little F , et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005;2:e330-e330
CrossRef | Web of Science | Medline4
Bhattarai A ,Ali AS ,Kachur SP , et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007;4:e309-e309
CrossRef | Web of Science | Medline5
Carrara VI ,Sirilak S ,Thonglairuam J , et al. Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med 2006;3:e183-e183
CrossRef | Web of Science | Medline6
Dondorp A ,Nosten F ,Stepniewska K , et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005;366:717-725
CrossRef | Web of Science | Medline7
Alker AP ,Lim P ,Sem R , et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 2007;76:641-647
Web of Science | Medline8
Denis MB ,Tsuyuoka R ,Poravuth Y , et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2006;11:1360-1366
CrossRef | Web of Science | Medline9
Denis MB ,Tsuyuoka R ,Lim P , et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health 2006;11:1800-1807
CrossRef | Web of Science | Medline10
Noedl H ,Se Y ,Schaecher K ,Smith BL ,Socheat D ,Fukuda MM . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008;359:2619-2620
Full Text | Web of Science | Medline11
Nosten F ,Luxemburger C ,ter Kuile FO , et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994;170:971-977[Erratum, J Infect Dis 1995;171:519.]
CrossRef | Web of Science | Medline12
Luxemburger C ,Thwai KL ,White NJ , et al. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg 1996;90:105-111
CrossRef | Web of Science | Medline13
Snounou G ,Zhu X ,Siripoon N , et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 1999;93:369-374[Erratum, Trans R Soc Trop Med Hyg 2000;94:65.]
CrossRef | Web of Science | Medline14
Genotyping to identify parasite populations. Geneva: World Health Organization, 2008.
15
Lindegardh N ,Hanpithakpong W ,Kamanikom B , et al. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci 2008;876:54-60
CrossRef | Web of Science | Medline16
Lindegardh N ,Dondorp AM ,Singhasivanon P ,White NJ ,Day NP . Validation and application of a liquid chromatographic-mass spectrometric method for determination of artesunate in pharmaceutical samples. J Pharm Biomed Anal 2007;45:149-153
CrossRef | Web of Science | Medline17
Webster HK ,Boudreau EF ,Pavanand K ,Yongvanitchit K ,Pang LW . Antimalarial drug susceptibility testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method. Am J Trop Med Hyg 1985;34:228-235
Web of Science | Medline18
Price RN ,Uhlemann AC ,Brockman A , et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004;364:438-447
CrossRef | Web of Science | Medline19
ter Kuile F ,White NJ ,Holloway P ,Pasvol G ,Krishna S . Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993;76:85-95
CrossRef | Web of Science | Medline20
Udomsangpetch R ,Pipitaporn B ,Krishna S , et al. Antimalarial drugs reduce cytoadherence and rosetting of Plasmodium falciparum. J Infect Dis 1996;173:691-698
CrossRef | Web of Science | Medline21
Keoluangkhot V ,Green MD ,Nyadong L ,Fernandez FM ,Mayxay M ,Newton PN . Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. Am J Trop Med Hyg 2008;78:552-555
Web of Science | Medline22
Jambou R ,Legrand E ,Niang M , et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005;366:1960-1963
CrossRef | Web of Science | Medline23
Eckstein-Ludwig U ,Webb RJ ,Van Goethem ID , et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003;424:957-961
CrossRef | Web of Science | Medline24
Ashley EA ,Stepniewska K ,Lindegardh N , et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health 2007;12:195-200
CrossRef | Web of Science | Medline25
Wongsrichanalai C ,Meshnick SR . Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 2008;14:716-719
CrossRef | Web of Science | Medline26
Angus BJ ,Thaiaporn I ,Chanthapadith K ,Suputtamongkol Y ,White NJ . Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 2002;46:778-782
CrossRef | Web of Science | Medline27
Carrara VI ,Zwang J ,Ashley EA , et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009;4:e4551-e4551
CrossRef | Web of Science | Medline28
Roper C ,Pearce R ,Nair S ,Sharp B ,Nosten F ,Anderson T . Intercontinental spread of pyrimethamine-resistant malaria. Science 2004;305:1124-1124
CrossRef | Web of Science | Medline29
Verdrager J . Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg 1986;89:277-289
Medline30
Yeung S ,Van Damme W ,Socheat D ,White NJ ,Mills A . Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J 2008;7:96-96
CrossRef | Web of Science | Medline31
Rathod PK ,McErlean T ,Lee PC . Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 1997;94:9389-9393
CrossRef | Web of Science | Medline
- Citing Articles (238)
Citing Articles
1
M. Siribié, A. Diarra, A. B. Tiono, I. Soulama, S. B. Sirima. (2012) Efficacité de l’artéméther-luméfantrine dans le traitement du paludisme simple de l’enfant en milieu rural au Burkina Faso en 2009. Bulletin de la Société de pathologie exotique
CrossRef2
Grace Olusola Gbotosho, Christian T. Happi, Olutayo Woranola, Oyindamola O. Abiodun, Akin Sowunmi, Ayoade M. Oduola. (2012) Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei. Parasitology Research 110:2, 895-899
CrossRef3
Adnan A. Bekhit, Ariaya Hymete, Ashenafi Damtew, Abdel Maaboud I. Mohamed, Alaa El-Din A. Bekhit. (2012) Synthesis and biological screening of some pyridine derivatives as anti-malarial agents. Journal of Enzyme Inhibition and Medicinal Chemistry 27:1, 69-77
CrossRef4
Christopher JL Murray, Lisa C Rosenfeld, Stephen S Lim, Kathryn G Andrews, Kyle J Foreman, Diana Haring, Nancy Fullman, Mohsen Naghavi, Rafael Lozano, Alan D Lopez. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. The Lancet 379:9814, 413-431
CrossRef5
Denis Zofou, Mathieu Tene, Pierre Tane, Vincent P. K. Titanji. (2012) Antimalarial drug interactions of compounds isolated from Kigelia africana (Bignoniaceae) and their synergism with artemether, against the multidrug-resistant W2mef Plasmodium falciparum strain. Parasitology Research 110:2, 539-544
CrossRef6
Robert L. Summers, Megan N. Nash, Rowena E. Martin. (2012) Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics. Cellular and Molecular Life Sciences
CrossRef7
Naina Sharma, Dinesh Mohanakrishnan, Amit Shard, Abhishek Sharma, Saima, Arun K. Sinha, Dinkar Sahal. (2012) Stilbene–Chalcone Hybrids: Design, Synthesis, and Evaluation as a New Class of Antimalarial Scaffolds That Trigger Cell Death through Stage Specific Apoptosis. Journal of Medicinal Chemistry 55:1, 297-311
CrossRef8
Paolo Mombelli, Matthias C. Witschel, Anthoni W. van Zijl, Julie G. Geist, Matthias Rottmann, Céline Freymond, Franz Röhl, Marcel Kaiser, Victoria Illarionova, Markus Fischer, Isabella Siepe, W. Bernd Schweizer, Reto Brun, François Diederich. (2012) Identification of 1,3-Diiminoisoindoline Carbohydrazides as Potential Antimalarial Candidates. ChemMedChem 7:1, 151-158
CrossRef9
Teresa Carbonara, Rossana Pascale, Maria Pia Argentieri, Paride Papadia, Francesco Paolo Fanizzi, Luciano Villanova, Pinarosa Avato. (2012) Phytochemical analysis of a herbal tea from Artemisia annua L. Journal of Pharmaceutical and Biomedical Analysis
CrossRef10
Claire Tacon, Eric M. Guantai, Peter J. Smith, Kelly Chibale. (2012) Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents. Bioorganic & Medicinal Chemistry 20:2, 893-902
CrossRef11
Mandana Afsharpad, Sedigheh Zakeri, Sakineh Pirahmadi, Navid Dinparast Djadid. (2012) Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine–pyrimethamine plus artesunate as the first line treatment in Iran. Acta Tropica 121:1, 13-18
CrossRef12
Tarig M Abdelgader, Abdalla M Ibrahim, Khalid A Elmardi, Sophie Githinji, Dejan Zurovac, Robert W Snow, Abdisalan M Noor. (2012) Progress towards implementation of ACT malaria case-management in public health facilities in the Republic of Sudan: a cluster- sample survey. BMC Public Health 12:1, 11
CrossRef13
Pardeep Singh, Parvesh Singh, Malkeet Kumar, Jiri Gut, Philip J. Rosenthal, Kewal Kumar, Vipan Kumar, Mohinder P. Mahajan, Krishna Bisetty. (2012) Synthesis, docking and in vitro antimalarial evaluation of bifunctional hybrids derived from β-lactams and 7-chloroquinoline using click chemistry. Bioorganic & Medicinal Chemistry Letters 22:1, 57-61
CrossRef14
Maria P. Crespo-Ortiz, Ming Q. Wei. (2012) Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug. Journal of Biomedicine and Biotechnology 2012, 1-18
CrossRef15
Katherine T Andrews, Ashraful Haque, Malcolm K Jones. (2012) HDAC inhibitors in parasitic diseases. Immunology and Cell Biology 90:1, 66-77
CrossRef16
Feroz Akhtar, M. Moshahid Alam Rizvi, Santosh Kumar Kar. (2012) Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnology Advances 30:1, 310-320
CrossRef17
W. Armand Guiguemde, Anang A. Shelat, Jose F. Garcia-Bustos, Thierry T. Diagana, Francisco-Javier Gamo, R. Kiplin Guy. (2012) Global Phenotypic Screening for Antimalarials. Chemistry & Biology 19:1, 116-129
CrossRef18
Nolé Tsabang, Patrick Valère Tsouh Fokou, Lauve Rachel Yamthe Tchokouaha, Béatrice Noguem, Issakou Bakarnga-Via, Mireille Sylviane Dongmo Nguepi, Bernard Aloys Nkongmeneck, Fabrice Fekam Boyom. (2012) Ethnopharmacological survey of Annonaceae medicinal plants used to treat malaria in four areas of Cameroon. Journal of Ethnopharmacology 139:1, 171-180
CrossRef19
Vivek Borhade, Sulabha Pathak, Shobhona Sharma, Vandana Patravale. (2012) Clotrimazole nanoemulsion for malaria chemotherapy. Part II: Stability assessment, in vivo pharmacodynamic evaluations and toxicological studies. International Journal of Pharmaceutics
CrossRef20
Brijesh S. Sisodia, Arvind S. Negi, Mahendra P. Darokar, Upendra N. Dwivedi, Suman P. S. Khanuja. (2012) Antiplasmodial Activity of Steroidal Chalcones: Evaluation of their Effect on Hemozoin Synthesis and the New Permeation Pathway of Plasmodium falciparum-Infected Erythrocyte Membrane. Chemical Biology & Drug Designno-no
CrossRef21
Eugénie Aimée Madiesse Kemgne, Wilfred Fon Mbacham, Fabrice Fekam Boyom, Paul Henri Amvam Zollo, Etienne Tsamo, Philip J. Rosenthal. (2012) In vitro sensitivity of Plasmodium falciparum field isolates to extracts from Cameroonian Annonaceae plants. Parasitology Research 110:1, 109-117
CrossRef22
Lena Serghides. (2012) The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria. PPAR Research 2012, 1-12
CrossRef23
Huang Huang, Weiqiang Lu, Xi Li, Xiaoli Cong, Hongmei Ma, Xiaofeng Liu, Yu Zhang, Peng Che, Ruoqun Ma, Honglin Li, Xu Shen, Hualiang Jiang, Jin Huang, Jin Zhu. (2012) Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent. Bioorganic & Medicinal Chemistry Letters 22:2, 958-962
CrossRef24
Moni Sharma, Kuldeep Chauhan, Shikha S. Chauhan, Ashok Kumar, Shiv Vardan Singh, Jitendra K. Saxena, Pooja Agarwal, Kumkum Srivastava, S. Raja Kumar, Sunil K. Puri, Priyanka Shah, M. I. Siddiqi, Prem M. S. Chauhan. (2012) Synthesis of hybrid 4-anilinoquinoline triazines as potent antimalarial agents, their in silico modeling and bioevaluation as Plasmodium falciparum transketolase and β-hematin inhibitors. MedChemComm 3:1, 71
CrossRef25
Krishnamoorthy Narayanasamy, Laura Chery, Analabha Basu, Manoj T. Duraisingh, Ananias Escalante, Joseph Fowble, Jennifer L. Guler, Thurston Herricks, Ashwani Kumar, Partha Majumder, Jennifer Maki, Anjali Mascarenhas, Janneth Rodrigues, Bikram Roy, Somdutta Sen, Jayanthi Shastri, Joseph Smith, Neena Valecha, John White, Pradipsinh K. Rathod. (2012) Malaria Evolution in South Asia: Knowledge for Control and Elimination. Acta Tropica
CrossRef26
Qin Cheng, Dennis Kyle, Michelle Gatton. (2012) Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy?. International Journal for Parasitology: Drugs and Drug Resistance
CrossRef27
Johanna Faist, Werner Seebacher, Robert Saf, Reto Brun, Marcel Kaiser, Robert Weis. (2012) New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds. European Journal of Medicinal Chemistry 47, 510-519
CrossRef28
Marcus J Rijken, Rose McGready, Machteld E Boel, Rini Poespoprodjo, Neeru Singh, Din Syafruddin, Stephen Rogerson, François Nosten. (2012) Malaria in pregnancy in the Asia-Pacific region. The Lancet Infectious Diseases 12:1, 75-88
CrossRef29
R. Matthew Cross, Niranjan K. Namelikonda, Tina S. Mutka, Lisa Luong, Dennis E. Kyle, Roman Manetsch. (2011) Synthesis, Antimalarial Activity, and Structure–Activity Relationship of 7-(2-Phenoxyethoxy)-4(1 H )-quinolones. Journal of Medicinal Chemistry 54:24, 8321-8327
CrossRef30
T. Mita, M. Venkatesan, J. Ohashi, R. Culleton, N. Takahashi, T. Tsukahara, M. Ndounga, L. Dysoley, H. Endo, F. Hombhanje, M. U. Ferreira, C. V. Plowe, K. Tanabe. (2011) Limited Geographical Origin and Global Spread of Sulfadoxine-Resistant dhps Alleles in Plasmodium falciparum Populations. Journal of Infectious Diseases 204:12, 1980-1988
CrossRef31
Mehdi A. Beniddir, Philippe Grellier, Philippe Rasoanaivo, Philippe M. Loiseau, Christian Bories, Vincent Dumontet, Françoise Guéritte, Marc Litaudon. (2011) Diarylheptanoid Glucosides from Pyrostria major and Their Antiprotozoal Activities. European Journal of Organic Chemistryn/a-n/a
CrossRef32
Nitendra K. Sahu, Sanjaykumar B. Bari, D. V. Kohli. (2011) Molecular modeling studies of some substituted chalcone derivatives as cysteine protease inhibitors. Medicinal Chemistry Research
CrossRef33
Sarah K. Volkman, Daouda Ndiaye, Mahamadou Diakite, Ousmane A. Koita, Davis Nwakanma, Rachel F. Daniels, Daniel J. Park, Daniel E. Neafsey, Marc A.T. Muskavitch, Donald J. Krogstad, Pardis C. Sabeti, Daniel L. Hartl, Dyann F. Wirth. (2011) Application of genomics to field investigations of malaria by the international centers of excellence for malaria research. Acta Tropica
CrossRef34
Connor O’Brien, Philipp P. Henrich, Neha Passi, David A. Fidock. (2011) Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Current Opinion in Infectious Diseases 24:6, 570-577
CrossRef35
Jean-François Trape, Adama Tall, Nafissatou Diagne, Ousmane Ndiath, Alioune B Ly, Joseph Faye, Fambaye Dieye-Ba, Clémentine Roucher, Charles Bouganali, Abdoulaye Badiane, Fatoumata Diene Sarr, Catherine Mazenot, Aïssatou Touré-Baldé, Didier Raoult, Pierre Druilhe, Odile Mercereau-Puijalon, Christophe Rogier, Cheikh Sokhna. (2011) Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. The Lancet Infectious Diseases 11:12, 925-932
CrossRef36
S. Vargas, K. Ndjoko Ioset, A.-E. Hay, J.-R. Ioset, S. Wittlin, K. Hostettmann. (2011) Screening medicinal plants for the detection of novel antimalarial products applying the inhibition of β-hematin formation. Journal of Pharmaceutical and Biomedical Analysis 56:5, 880-886
CrossRef37
Nicola Gargano, Fabio Cenci, Quique Bassat. (2011) Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Tropical Medicine & International Health 16:12, 1466-1473
CrossRef38
Paul Horrocks, Samantha Fallon, Laura Denman, Oliver Devine, Liam J. Duffy, Anthony Harper, Emma-Louise Meredith, Sandra Hasenkamp, Adam Sidaway, Daniel Monnery, Theresa R. Phillips, Steven M. Allin. (2011) Synthesis and evaluation of a novel series of indoloisoquinolines as small molecule anti-malarial leads. Bioorganic & Medicinal Chemistry Letters
CrossRef39
Akira Sato, Satoru Kawai, Akiko Hiramoto, Masayuki Morita, Natsuki Tanigawa, Yukari Nakase, Yuka Komichi, Masahiro Matsumoto, Osamu Hiraoka, Kazuyuki Hiramoto, Hidekazu Tokuhara, Araki Masuyama, Masatomo Nojima, Kazutaka Higaki, Hikoya Hayatsu, Yusuke Wataya, Hye-Sook Kim. (2011) Antimalarial activity of 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) and its carboxylic acid derivatives. Parasitology International 60:4, 488-492
CrossRef40
Michèle van Vugt, Anne van Beest, Elisa Sicuri, Maurits van Tulder, Martin P Grobusch. (2011) Malaria treatment and prophylaxis in endemic and nonendemic countries: evidence on strategies and their cost–effectiveness. Future Microbiology 6:12, 1485-1500
CrossRef41
2011. Bibliography. , 211-244.
CrossRef42
David J. Lowes, W. Armand Guiguemde, Michele C. Connelly, Fangyi Zhu, Martina S. Sigal, Julie A. Clark, Andrew S. Lemoff, Joseph L. Derisi, Emily B. Wilson, R. Kiplin Guy. (2011) Optimization of Propafenone Analogues as Antimalarial Leads. Journal of Medicinal Chemistry 54:21, 7477-7485
CrossRef43
Pulin Che, Long Cui, Olaf Kutsch, Liwang Cui, Qianjun Li. (2011) Validating a Firefly Luciferase-Based High-Throughput Screening Assay for Antimalarial Drug Discovery. ASSAY and Drug Development Technologies111103062554006
CrossRef44
S. HUIJBEN, D. G. SIM, W. A. NELSON, A. F. READ. (2011) The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection. Journal of Evolutionary Biology 24:11, 2410-2422
CrossRef45
Aparup Das, Anupkumar R. Anvikar, Lauren J. Cator, Ramesh C. Dhiman, Alex Eapen, Neelima Mishra, Bhupinder N. Nagpal, Nutan Nanda, Kamaraju Raghavendra, Andrew F. Read, Surya K. Sharma, Om P. Singh, Vineeta Singh, Photini Sinnis, Harish C. Srivastava, Steven A. Sullivan, Patrick L. Sutton, Matthew B. Thomas, Jane M. Carlton, Neena Valecha. (2011) Malaria in India: The Center for the Study of Complex Malaria in India. Acta Tropica
CrossRef46
Christoph T. Behrendt, Andrea Kunfermann, Victoria Illarionova, An Matheeussen, Miriam K. Pein, Tobias Gräwert, Johannes Kaiser, Adelbert Bacher, Wolfgang Eisenreich, Boris Illarionov, Markus Fischer, Louis Maes, Michael Groll, Thomas Kurz. (2011) Reverse Fosmidomycin Derivatives against the Antimalarial Drug Target IspC (Dxr). Journal of Medicinal Chemistry 54:19, 6796-6802
CrossRef47
A Laroque, G Min-Oo, M Tam, I Radovanovic, M M Stevenson, P Gros. (2011) Genetic control of susceptibility to infection with Plasmodium chabaudi chabaudi AS in inbred mouse strains. Genes and Immunity
CrossRef48
John C Sinclair, Marcela Bottino, Richard M Cowett, Marcela Bottino. 2011. Interventions for prevention of neonatal hyperglycemia in very low birth weight infants. .
CrossRef49
Jyoti Agarwal, Suriya Pratap Singh, Debabrata Chanda, Dnyaneshwar Umrao Bawankule, Rajendra Singh Bhakuni, Anirban Pal. (2011) Antiplasmodial activity of artecyclopentyl mether a new artemisinin derivative and its effect on pathogenesis in Plasmodium yoelii nigeriensis infected mice. Parasitology Research 109:4, 1003-1008
CrossRef50
Rita Piedade, José Pedro Gil. (2011) The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opinion on Drug Metabolism & Toxicology 7:10, 1185-1200
CrossRef51
COLIN J. SUTHERLAND, HAMZA BABIKER, MARGARET J. MACKINNON, LISA RANFORD-CARTWRIGHT, BADRIA BABIKER EL SAYED. (2011) Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?. Parasitology 138:12, 1459-1468
CrossRef52
Kailash C. Pandey. (2011) Centenary celebrations article. Journal of Parasitic Diseases 35:2, 94-103
CrossRef53
J-H Ch'Ng, K Liew, A S-P Goh, E Sidhartha, K S-W Tan. (2011) Drug-induced permeabilization of parasite's digestive vacuole is a key trigger of programmed cell death in Plasmodium falciparum. Cell Death and Disease 2:10, e216
CrossRef54
Christine Mara, Enda Dempsey, Angus Bell, James W. Barlow. (2011) Synthesis and evaluation of phosphoramidate and phosphorothioamidate analogues of amiprophos methyl as potential antimalarial agents. Bioorganic & Medicinal Chemistry Letters 21:20, 6180-6183
CrossRef55
Krijn P. Paaijmans, Matthew B. Thomas. (2011) Health: Wealth versus warming. Nature Climate Change 1:7, 349-350
CrossRef56
S Christensen, Ib Bygbjerg. 2011. Drugs for the Neglected Disease Malaria Based on Natural Products. , 525-550.
CrossRef57
Dondorp, Arjen M., Fairhurst, Rick M., Slutsker, Laurence, MacArthur, John R., M.D., Joel G. BremanGuerin, Philippe J., Wellems, Thomas E., Ringwald, Pascal, Newman, Robert D., Plowe, Christopher V., . (2011) The Threat of Artemisinin-Resistant Malaria. New England Journal of Medicine 365:12, 1073-1075
Full Text58
Yanhui Zhang, Yanwei Qi, Jian Li, Shengfa Liu, Lingxian Hong, Tianlong Lin, Carole Long, Xin-zhuan Su. (2011) A new malaria antigen produces partial protection against Plasmodium yoelii challenge. Parasitology Research
CrossRef59
Renato T. Skerlj, Cecilia M. Bastos, Michael L. Booker, Martin L. Kramer, Robert H. Barker, Cassandra A. Celatka, Thomas J. O’Shea, Benito Munoz, Amar Bir Sidhu, Joseph F. Cortese, Sergio Wittlin, Petros Papastogiannidis, Inigo Angulo-Barturen, Maria Belen Jimenez-Diaz, Edmund Sybertz. (2011) Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria. ACS Medicinal Chemistry Letters 2:9, 708-713
CrossRef60
Philippe Leprohon, Danielle Légaré, Marc Ouellette. (2011) ABC transporters involved in drug resistance in human parasites. Essays in Biochemistry 50:1, 121-144
CrossRef61
E. Paige Stout, Serena Cervantes, Jacques Prudhomme, Stefan France, James J. La Clair, Karine Le Roch, Julia Kubanek. (2011) Bromophycolide A Targets Heme Crystallization in the Human Malaria Parasite Plasmodium falciparum. ChemMedChem 6:9, 1572-1577
CrossRef62
F. Bruxel, S. Cojean, A. Bochot, H. Teixeira, C. Bories, P.-M. Loiseau, E. Fattal. (2011) Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II. International Journal of Pharmaceutics 416:2, 402-409
CrossRef63
Ruth Devakaram, David StC. Black, Katherine T. Andrews, Gillian M. Fisher, Rohan A. Davis, Naresh Kumar. (2011) Synthesis and antimalarial evaluation of novel benzopyrano[4,3-b]benzopyran derivatives. Bioorganic & Medicinal Chemistry 19:17, 5199-5206
CrossRef64
Akira Sato, Akiko Hiramoto, Masayuki Morita, Masahiro Matsumoto, Yuka Komich, Yukari Nakase, Natsuki Tanigawa, Osamu Hiraoka, Kazuyuki Hiramoto, Hikoya Hayatsu, Kazutaka Higaki, Satoru Kawai, Araki Masuyama, Masatomo Nojima, Yusuke Wataya, Hye-Sook Kim. (2011) Antimalarial activity of endoperoxide compound 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol. Parasitology International 60:3, 270-273
CrossRef65
Roselyne Nzangue Tepongning, Leonardo Lucantoni, Cinzia Carla Nasuti, Geme Urge Dori, Serge Rakiswende Yerbanga, Giulio Lupidi, Carlotta Marini, Giacomo Rossi, Fulvio Esposito, Annette Habluetzel. (2011) Potential of a Khaya ivorensis – Alstonia boonei extract combination as antimalarial prophylactic remedy. Journal of Ethnopharmacology 137:1, 743-751
CrossRef66
Alexis Nzila, Zhenkun Ma, Kelly Chibale. (2011) Drug repositioning in the treatment of malaria and TB. Future Medicinal Chemistry 3:11, 1413-1426
CrossRef67
Louis H. Miller, Xinzhuan Su. (2011) Artemisinin: Discovery from the Chinese Herbal Garden. Cell 146:6, 855-858
CrossRef68
D. Fegan, M. J. Glennon. (2011) Erythrocytapheresis treatment in severe malaria. Internal Medicine Journal 41:9, 709-710
CrossRef69
Sandra Gemma, Sanil Kunjir, Salvatore Sanna Coccone, Margherita Brindisi, Vittoria Moretti, Simone Brogi, Ettore Novellino, Nicoletta Basilico, Silvia Parapini, Donatella Taramelli, Giuseppe Campiani, Stefania Butini. (2011) Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues. Journal of Medicinal Chemistry 54:16, 5949-5953
CrossRef70
Kancharla Papireddy, Martin Smilkstein, Jane Xu Kelly, Shweta, Shaimaa M. Salem, Mamoun Alhamadsheh, Stuart W. Haynes, Gregory L. Challis, Kevin A. Reynolds. (2011) Antimalarial Activity of Natural and Synthetic Prodiginines. Journal of Medicinal Chemistry 54:15, 5296-5306
CrossRef71
J. Yuan, K. C.-C. Cheng, R. L. Johnson, R. Huang, S. Pattaradilokrat, A. Liu, R. Guha, D. A. Fidock, J. Inglese, T. E. Wellems, C. P. Austin, X.-z. Su. (2011) Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets. Science 333:6043, 724-729
CrossRef72
F. Astelbauer, J. Walochnik. (2011) Antiprotozoal compounds: state of the art and new developments. International Journal of Antimicrobial Agents 38:2, 118-124
CrossRef73
Tzu-Shean Feng, Eric M. Guantai, Margo Nell, Constance E.J. van Rensburg, Kanyile Ncokazi, Timothy J. Egan, Heinrich C. Hoppe, Kelly Chibale. (2011) Effects of highly active novel artemisinin–chloroquinoline hybrid compounds on β-hematin formation, parasite morphology and endocytosis in Plasmodium falciparum. Biochemical Pharmacology 82:3, 236-247
CrossRef74
Gundula Min-Oo, Philippe Gros. (2011) Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria. Mammalian Genome 22:7-8, 486-494
CrossRef75
R. Matthew Cross, Jordany R. Maignan, Tina S. Mutka, Lisa Luong, Justin Sargent, Dennis E. Kyle, Roman Manetsch. (2011) Optimization of 1,2,3,4-Tetrahydroacridin-9(10 H )-ones as Antimalarials Utilizing Structure–Activity and Structure–Property Relationships. Journal of Medicinal Chemistry 54:13, 4399-4426
CrossRef76
N. Klonis, M. P. Crespo-Ortiz, I. Bottova, N. Abu-Bakar, S. Kenny, P. J. Rosenthal, L. Tilley. (2011) Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proceedings of the National Academy of Sciences 108:28, 11405-11410
CrossRef77
Niklas Lindegardh, Warunee Hanpithakpong, Benjamas Kamanikom, Janhom Pattayaso, Pratap Singhasivanon, Nicholas J White, Nicholas PJ Day. (2011) Quantification of dihydroartemisinin, artesunate and artemisinin in human blood: overcoming the technical challenge of protecting the peroxide bridge. Bioanalysis 3:14, 1613-1624
CrossRef78
Henry M Staines, Simon L Croft, Paul D Horrocks. (2011) Developing novel strategies to prevent parasitic infections. Expert Review of Anti-infective Therapy 9:7, 783-785
CrossRef79
J. Dewald Steyn, Lubbe Wiesner, Lissinda H. du Plessis, Anne F. Grobler, Peter J. Smith, Wing-Chi Chan, Richard K. Haynes, Awie F. Kotzé. (2011) Absorption of the novel artemisinin derivatives artemisone and artemiside: Potential application of Pheroid™ technology. International Journal of Pharmaceutics 414:1-2, 260-266
CrossRef80
Ambrose Talisuna, Seraphine Adibaku, Grant Dorsey, Moses R. Kamya, Philip J. Rosenthal. (2011) Malaria in Uganda: Challenges to control on the long road to elimination. II. The path forward. Acta Tropica
CrossRef81
B. Meessen, M. Bigdeli, K. Chheng, K. Decoster, P. Ir, C. Men, W. Van Damme. (2011) Composition of pluralistic health systems: how much can we learn from household surveys? An exploration in Cambodia. Health Policy and Planning 26:Suppl. 1, i30-i44
CrossRef82
Ramesh Gujjar, Farah El Mazouni, Karen L. White, John White, Sharon Creason, David M. Shackleford, Xiaoyi Deng, William N. Charman, Ian Bathurst, Jeremy Burrows, David M. Floyd, David Matthews, Frederick S. Buckner, Susan A. Charman, Margaret A. Phillips, Pradipsinh K. Rathod. (2011) Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice. Journal of Medicinal Chemistry 54:11, 3935-3949
CrossRef83
T. Antao, I. M. Hastings. (2011) Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. Proceedings of the Royal Society B: Biological Sciences 278:1712, 1705-1712
CrossRef84
Shanthi Kappagoda, Upinder Singh, Brian G. Blackburn. (2011) Antiparasitic Therapy. Mayo Clinic Proceedings 86:6, 561-583
CrossRef85
Case McNamara, Elizabeth A Winzeler. (2011) Target identification and validation of novel antimalarials. Future Microbiology 6:6, 693-704
CrossRef86
Lin H. Chen. (2011) Clinical Trial Report: Double-Dose Chloroquine for Treatment of Plasmodium falciparum Malaria in Guinea-Bissau. Current Infectious Disease Reports 13:3, 205-206
CrossRef87
Ines Petersen, Richard Eastman, Michael Lanzer. (2011) Drug-resistant malaria: Molecular mechanisms and implications for public health. FEBS Letters 585:11, 1551-1562
CrossRef88
John Okombo, Eric Ohuma, Stephane Picot, Alexis Nzila. (2011) Update on genetic markers of quinine resistance in Plasmodium falciparum. Molecular and Biochemical Parasitology 177:2, 77-82
CrossRef89
Leann Tilley, Matthew W.A. Dixon, Kiaran Kirk. (2011) The Plasmodium falciparum-infected red blood cell. The International Journal of Biochemistry & Cell Biology 43:6, 839-842
CrossRef90
Eric M. Guantai, Kanyile Ncokazi, Timothy J. Egan, Jiri Gut, Philip J. Rosenthal, Ravi Bhampidipati, Anitha Kopinathan, Peter J. Smith, Kelly Chibale. (2011) Enone– and Chalcone–Chloroquinoline Hybrid Analogues: In Silico Guided Design, Synthesis, Antiplasmodial Activity, in Vitro Metabolism, and Mechanistic Studies. Journal of Medicinal Chemistry 54:10, 3637-3649
CrossRef91
Baichen Zhang, Kristin M. Watts, Dana Hodge, Lisa M. Kemp, David A. Hunstad, Leslie M. Hicks, Audrey R. Odom. (2011) A Second Target of the Antimalarial and Antibacterial Agent Fosmidomycin Revealed by Cellular Metabolic Profiling. Biochemistry 50:17, 3570-3577
CrossRef92
Mark Mascal, Kyle V. Modes, Asuman Durmus. (2011) Concise Photochemical Synthesis of the Antimalarial Indole Alkaloid Decursivine. Angewandte Chemie International Edition 50:19, 4445-4446
CrossRef93
Mark Mascal, Kyle V. Modes, Asuman Durmus. (2011) Concise Photochemical Synthesis of the Antimalarial Indole Alkaloid Decursivine. Angewandte Chemie 123:19, 4537-4538
CrossRef94
Jana Held, Shahid A. Soomro, Peter G. Kremsner, F. Herwig Jansen, Benjamin Mordmüller. (2011) In vitro activity of new artemisinin derivatives against Plasmodium falciparum clinical isolates from Gabon. International Journal of Antimicrobial Agents 37:5, 485-488
CrossRef95
Emmanuel Bottieau, Marc Vekemans, Alfons Van Gompel. (2011) Therapy of vector-borne protozoan infections in nonendemic settings. Expert Review of Anti-infective Therapy 9:5, 583-608
CrossRef96
T. Antao, I. M. Hastings. (2011) ogaraK: a population genetics simulator for malaria. Bioinformatics 27:9, 1335-1336
CrossRef97
Tran Tinh Hien, Warunee Hanpithakpong, Nguyen Thanh Truong, Nguyen Thi Dung, Pham Van Toi, Jeremy Farrar, Niklas Lindegardh, Joel Tarning, Michael Ashton. (2011) Orally Formulated Artemisinin in Healthy Fasting Vietnamese Male Subjects: A Randomized, Four-Sequence, Open-Label, Pharmacokinetic Crossover Study. Clinical Therapeutics 33:5, 644-654
CrossRef98
Tzu-Shean Feng, Eric M. Guantai, Margo J. Nell, Constance E.J. van Rensburg, Heinrich C. Hoppe, Kelly Chibale. (2011) Antiplasmodial and antitumor activity of dihydroartemisinin analogs derived via the aza-Michael addition reaction. Bioorganic & Medicinal Chemistry Letters 21:10, 2882-2886
CrossRef99
Rahul Balasaheb Aher, Gajanan Wanare, Neha Kawathekar, Ravi Ranjan Kumar, Naveen Kumar Kaushik, Dinkar Sahal, Virander Singh Chauhan. (2011) Dibenzylideneacetone analogues as novel Plasmodium falciparum inhibitors. Bioorganic & Medicinal Chemistry Letters 21:10, 3034-3036
CrossRef100
Vincent K. Zishiri, Roger Hunter, Peter J. Smith, Dale Taylor, Robert Summers, Kiaran Kirk, Rowena E. Martin, Timothy J. Egan. (2011) A series of structurally simple chloroquine chemosensitizing dibemethin derivatives that inhibit chloroquine transport by PfCRT. European Journal of Medicinal Chemistry 46:5, 1729-1742
CrossRef101
Akintunde Sowunmi, Grace Olusola Gbotosho, Christian Tientcha Happi, Onikepe Folarin, Titilope Okuboyejo, Obaro Michael, Bayo Fatunmbi. (2011) Use of Area Under the Curve to Evaluate the Effects of Antimalarial Drugs on Malaria-Associated Anemia After Treatment. American Journal of Therapeutics 18:3, 190-197
CrossRef102
Liwang Cui, Guiyun Yan, Jetsumon Sattabongkot, Bin Chen, Yaming Cao, Qi Fan, Daniel Parker, Jeeraphat Sirichaisinthop, Xin-zhuan Su, Henglin Yang, Zhaoqing Yang, Baomin Wang, Guofa Zhou. (2011) Challenges and prospects for malaria elimination in the Greater Mekong Subregion. Acta Tropica
CrossRef103
Fabrice Fekam Boyom, Patrick Valere Tsouh Fokou, Lauve Rachel Tchokouaha Yamthe, Alvine Ngoutane Mfopa, Eugénie Madiesse Kemgne, Wilfred Fon Mbacham, Etienne Tsamo, Paul Henri Amvam Zollo, Jiri Gut, Philip J. Rosenthal. (2011) Potent antiplasmodial extracts from Cameroonian Annonaceae. Journal of Ethnopharmacology 134:3, 717-724
CrossRef104
Sumit S. Mahajan, Edgar Deu, Erica M. W. Lauterwasser, Melissa J. Leyva, Jonathan A. Ellman, Matthew Bogyo, Adam R. Renslo. (2011) A Fragmenting Hybrid Approach for Targeted Delivery of Multiple Therapeutic Agents to the Malaria Parasite. ChemMedChem 6:3, 415-419
CrossRef105
B. S. Franklin, S. T. Ishizaka, M. Lamphier, F. Gusovsky, H. Hansen, J. Rose, W. Zheng, M. A. Ataide, R. B. de Oliveira, D. T. Golenbock, R. T. Gazzinelli. (2011) Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proceedings of the National Academy of Sciences 108:9, 3689-3694
CrossRef106
Liwang Cui, Guiyun Yan, Jetsumon Sattabongkot, Yaming Cao, Bin Chen, Xiaoguang Chen, Qi Fan, Qiang Fang, Somchai Jongwutiwes, Daniel Parker, Jeeraphat Sirichaisinthop, Myat Phone Kyaw, Xin-zhuan Su, Henglin Yang, Zhaoqing Yang, Baomin Wang, Jianwei Xu, Bin Zheng, Daibin Zhong, Guofa Zhou. (2011) Malaria in the Greater Mekong Subregion: Heterogeneity and complexity. Acta Tropica
CrossRef107
J.W. Gathirwa, G.M. Rukunga, P.G. Mwitari, N.M. Mwikwabe, C.W. Kimani, C.N. Muthaura, D.M. Kiboi, R.M. Nyangacha, S.A. Omar. (2011) Traditional herbal antimalarial therapy in Kilifi district, Kenya. Journal of Ethnopharmacology 134:2, 434-442
CrossRef108
John N. Alumasa, Alexander P. Gorka, Leah B. Casabianca, Erica Comstock, Angel C. de Dios, Paul D. Roepe. (2011) The hydroxyl functionality and a rigid proximal N are required for forming a novel non-covalent quinine-heme complex. Journal of Inorganic Biochemistry 105:3, 467-475
CrossRef109
Henri J. Vial, Diana Penarete, Sharon Wein, Sergio Caldarelli, Laurent Fraisse, Suzanne Peyrottes. 2011. Lipids as Drug Targets for Malaria Therapy. , 137-162.
CrossRef110
Denis Matovu Kasozi, Stefan Rahlfs, Katja Becker. 2011. Current Aspects of Endoperoxides in Antiparasitic Chemotherapy. , 413-430.
CrossRef111
Monika S. Walczak, Krystyna Lawniczak-Jablonska, Anna Wolska, Andrzej Sienkiewicz, Liliana Suárez, Aaron J. Kosar, D. Scott Bohle. (2011) Understanding Chloroquine Action at the Molecular Level in Antimalarial Therapy: X-ray Absorption Studies in Dimethyl Sulfoxide Solution. The Journal of Physical Chemistry B 115:5, 1145-1150
CrossRef112
Rhea Longley, Clare Smith, Anny Fortin, Joanne Berghout, Brendan McMorran, Gaétan Burgio, Simon Foote, Philippe Gros. (2011) Host resistance to malaria: using mouse models to explore the host response. Mammalian Genome 22:1-2, 32-42
CrossRef113
Patrick Nef. (2011) Building biotechnology by design: Role of biotechnology in development. Journal of Commercial Biotechnology 17:1, 4-6
CrossRef114
Masato Iwatsuki, Shohei Takada, Mihoko Mori, Aki Ishiyama, Miyuki Namatame, Aki Nishihara-Tsukashima, Kenichi Nonaka, Rokuro Masuma, Kazuhiko Otoguro, Kazuro Shiomi, Satoshi Ōmura. (2011) In vitro and in vivo antimalarial activity of puberulic acid and its new analogs, viticolins A–C, produced by Penicillium sp. FKI-4410. The Journal of Antibiotics 64:2, 183-188
CrossRef115
Jose Acuin, Rebecca Firestone, Thein Thein Htay, Geok Lin Khor, Hasbullah Thabrany, Vonthanak Saphonn, Suwit Wibulpolprasert. (2011) Southeast Asia: an emerging focus for global health. The Lancet 377:9765, 534-535
CrossRef116
Serena Tschan, Benjamin Mordmüller, Jürgen FJ Kun. (2011) Threonine peptidases as drug targets against malaria. Expert Opinion on Therapeutic Targets1-14
CrossRef117
P. A. Buffet, I. Safeukui, G. Deplaine, V. Brousse, V. Prendki, M. Thellier, G. D. Turner, O. Mercereau-Puijalon. (2011) The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117:2, 381-392
CrossRef118
S. Saralamba, W. Pan-Ngum, R. J. Maude, S. J. Lee, J. Tarning, N. Lindegardh, K. Chotivanich, F. Nosten, N. P. J. Day, D. Socheat, N. J. White, A. M. Dondorp, L. J. White. (2011) Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proceedings of the National Academy of Sciences 108:1, 397-402
CrossRef119
J. Kevin Baird, Claudia Surjadjaja. (2011) Consideration of ethics in primaquine therapy against malaria transmission. Trends in Parasitology 27:1, 11-16
CrossRef120
Gregory J. Crowther, Alberto J. Napuli, James H. Gilligan, Kerstin Gagaring, Rachel Borboa, Carolyn Francek, Zhong Chen, Eleanor F. Dagostino, Justin B. Stockmyer, Yu Wang, Philip P. Rodenbough, Lisa J. Castaneda, David J. Leibly, Janhavi Bhandari, Michael H. Gelb, Achim Brinker, Ingo H. Engels, Jennifer Taylor, Arnab K. Chatterjee, Pascal Fantauzzi, Richard J. Glynne, Wesley C. Van Voorhis, Kelli L. Kuhen. (2011) Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Molecular and Biochemical Parasitology 175:1, 21-29
CrossRef121
Frank Shann, Andrew C. Argent, Suchitra Ranjit. 2011. Pediatric Intensive Care in Developing Countries. , 164-178.
CrossRef122
NJ White. (2011) The parasite clearance curve. Malaria Journal 10:1, 278
CrossRef123
Kanyanan Kritsiriwuthinan, Sastra Chaotheing, Philip J Shaw, Chayaphat Wongsombat, Porntip Chavalitshewinkoon-Petmitr, Sumalee Kamchonwongpaisan. (2011) Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine. Malaria Journal 10:1, 242
CrossRef124
Andrea Codd, Franka Teuscher, Dennis E Kyle, Qin Cheng, Michelle L Gatton. (2011) Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malaria Journal 10:1, 56
CrossRef125
Hervé Menan, Oumar Faye, Albert Same-Ekobo, Agbaya Serge S Oga, Babacar Faye, Christiane P Kiki Barro, Thomas Kuete, Jean-Louis N'diaye, Ama-Moor Vicky, Rogert Tine, William Yavo, Dieynaba Kane, Kondo F Kassi, Moussa Kone. (2011) Comparative study of the efficacy and tolerability of dihydroartemisinin - piperaquine - trimethoprim versus artemether - lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malaria Journal 10:1, 185
CrossRef126
Shunmay Yeung, Edith Patouillard, Henrietta Allen, Duong Socheat. (2011) Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malaria Journal 10:1, 243
CrossRef127
Tanya Shewchuk, Kathryn A O'Connell, Catherine Goodman, Kara Hanson, Steven Chapman, Desmond Chavasse. (2011) The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malaria Journal 10:1, 325
CrossRef128
Guido JH Bastiaens, Erik Schaftenaar, Arnold Ndaro, Monique Keuter, Teun Bousema, Seif A Shekalaghe. (2011) Malaria diagnostic testing and treatment practices in three different Plasmodium falciparum transmission settings in Tanzania: before and after a government policy change. Malaria Journal 10:1, 76
CrossRef129
Carsten Wrenger, Ingrid B. Müller, Anna J. Schifferdecker, Rishabh Jain, Rositsa Jordanova, Matthew R. Groves. (2011) Specific Inhibition of the Aspartate Aminotransferase of Plasmodium falciparum. Journal of Molecular Biology 405:4, 956-971
CrossRef130
Amnat Khamsiriwatchara, Piyaporn Wangroongsarb, Julie Thwing, James Eliades, Wichai Satimai, Charles Delacollette, Jaranit Kaewkungwal. (2011) Respondent-driven sampling on the Thailand-Cambodia border. I. Can malaria cases be contained in mobile migrant workers?. Malaria Journal 10:1, 120
CrossRef131
Bécaye Fall, Silmane Diawara, Kowry Sow, Eric Baret, Bakary Diatta, Khadidiatou B Fall, Pape S Mbaye, Fatou Fall, Yaya Diémé, Christophe Rogier, Boubacar Wade, Raymond Bercion, Bruno Pradines. (2011) Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malaria Journal 10:1, 310
CrossRef132
Denis Zofou, Mathieu Tene, Moses N. Ngemenya, Pierre Tane, Vincent P. K. Titanji. (2011) In Vitro Antiplasmodial Activity and Cytotoxicity of Extracts of Selected Medicinal Plants Used by Traditional Healers of Western Cameroon. Malaria Research and Treatment 2011, 1-6
CrossRef133
Patrice N Mimche, Donatella Taramelli, Livia Vivas. (2011) The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malaria Journal 10:Suppl 1, S10
CrossRef134
Ramesh Chandra, L.M. Tripathi, J.K. Saxena, S.K. Puri. (2011) Implication of intracellular glutathione and its related enzymes on resistance of malaria parasites to the antimalarial drug arteether. Parasitology International 60:1, 97-100
CrossRef135
Piyaporn Wangroongsarb, Wichai Satimai, Amnat Khamsiriwatchara, Julie Thwing, James M Eliades, Jaranit Kaewkungwal, Charles Delacollette. (2011) Respondent-driven sampling on the Thailand-Cambodia border. II. Knowledge, perception, practice and treatment-seeking behaviour of migrants in malaria endemic zones. Malaria Journal 10:1, 117
CrossRef136
Sachel Mok, Mallika Imwong, Margaret J Mackinnon, Joan Sim, Ramya Ramadoss, Poravuth Yi, Mayfong Mayxay, Kesinee Chotivanich, Kek-Yee Liong, Bruce Russell, Duong Socheat, Paul N Newton, Nicholas PJ Day, Nicholas J White, Peter R Preiser, François Nosten, Arjen M Dondorp, Zbynek Bozdech. (2011) Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12:1, 391
CrossRef137
Timothy NC Wells. (2011) Natural products as starting points for future anti-malarial therapies: going back to our roots?. Malaria Journal 10:Suppl 1, S3
CrossRef138
Rong Liu, Hui-Fen Dong, Yi Guo, Qin-Ping Zhao, Ming-Sen Jiang. (2011) Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasites & Vectors 4:1, 201
CrossRef139
Bruno Pradines, Lionel Bertaux, Christelle Pomares, Pascal Delaunay, Pierre Marty. (2011) Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Malaria Journal 10:1, 268
CrossRef140
Roma Chilengi, Rashid Juma, Ahmed M Abdallah, Mahfudh Bashraheil, Hudson Lodenyo, Priscilla Nyakundi, Evelyn Anabwani, Amina Salim, Gabriel Mwambingu, Ednah Wenwa, Julie Jemutai, Chemtai Kipkeu, George O Oyoo, Simon N Muchohi, Gilbert Kokwaro, Tim Niehues, Trudie Lang, Alexis Nzila. (2011) A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. Malaria Journal 10:1, 63
CrossRef141
Masataka Ihara. (2011) Discovery of New Anti-Protozoan Agents Having Novel Mode of Action. HETEROCYCLES 83:8, 1727
CrossRef142
Finn Andersen, Nick M Douglas, Dorina Bustos, Gawrie Galappaththy, Gao Qi, Michelle S Hsiang, Rita Kusriastuti, Kamini Mendis, George Taleo, Maxine Whittaker, Ric N Price, Lorenz von Seidlein. (2011) Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades. Malaria Journal 10:1, 131
CrossRef143
Tim Anderson, Standwell Nkhoma, Andrea Ecker, David Fidock. (2011) How can we identify parasite genes that underlie antimalarial drug resistance?. Pharmacogenomics 12:1, 59-85
CrossRef144
Ksenija Slavic, Sanjeev Krishna, Elvira T Derbyshire, Henry M Staines. (2011) Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa. Malaria Journal 10:1, 165
CrossRef145
Ana Carolina AV Kayano, Stefanie CP Lopes, Fernanda G Bueno, Elaine C Cabral, Wanessa C Souza-Neiras, Lucy M Yamauchi, Mary A Foglio, Marcos N Eberlin, João Mello, Fabio TM Costa. (2011) In vitro and in vivo assessment of the anti-malarial activity of Caesalpinia pluviosa. Malaria Journal 10:1, 112
CrossRef146
Delphine Margout, Florence Gattacceca, Georges Moarbess, Sharon Wein, Christophe Tran van Ba, Samuel Le Pape, Olivier Berger, Roger Escale, Henri J. Vial, Françoise M.M. Bressolle. (2011) Pharmacokinetic properties and metabolism of a new potent antimalarial N-alkylamidine compound, M64, and its corresponding bioprecursors. European Journal of Pharmaceutical Sciences 42:1-2, 81-90
CrossRef147
F. Bruneel. (2011) Traitement du paludisme grave par artésunate intraveineux. Réanimation 21:S2, 399-405
CrossRef148
Jennifer A Flegg, Philippe J Guerin, Nicholas J White, Kasia Stepniewska. (2011) Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malaria Journal 10:1, 339
CrossRef149
Kris M Jamsen, Stephen B Duffull, Joel Tarning, Niklas Lindegardh, Nicholas J White, Julie A Simpson. (2011) Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malaria Journal 10:1, 181
CrossRef150
J. Ursing, P.-E. Kofoed, A. Rodrigues, D. Blessborn, R. Thoft-Nielsen, A. Bjorkman, L. Rombo. (2011) Similar Efficacy and Tolerability of Double-Dose Chloroquine and Artemether-Lumefantrine for Treatment of Plasmodium falciparum Infection in Guinea-Bissau: A Randomized Trial. Journal of Infectious Diseases 203:1, 109-116
CrossRef151
Falgun Shah, Yunshan Wu, Jiri Gut, Yakambram Pedduri, Jennifer Legac, Philip J. Rosenthal, Mitchell A. Avery. (2011) Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors. MedChemComm 2:12, 1201
CrossRef152
John VW Becker, Marina M van der Merwe, Anna C van Brummelen, Pamisha Pillay, Bridget G Crampton, Edwin M Mmutlane, Chris Parkinson, Fanie R van Heerden, Neil R Crouch, Peter J Smith, Dalu T Mancama, Vinesh J Maharaj. (2011) In vitro anti-plasmodial activity of Dicoma anomala subsp. gerrardii (Asteraceae): identification of its main active constituent, structure-activity relationship studies and gene expression profiling. Malaria Journal 10:1, 295
CrossRef153
Denis Zofou, Théodora K Kowa, Hippolyte K Wabo, Moses N Ngemenya, Pierre Tane, Vincent PK Titanji. (2011) Hypericum lanceolatum (Hypericaceae) as a potential source of new anti-malarial agents: a bioassay-guided fractionation of the stem bark. Malaria Journal 10:1, 167
CrossRef154
Joan Vallès, Sònia Garcia, Oriane Hidalgo, Joan Martín, Jaume Pellicer, María Sanz, Teresa Garnatje. 2011. Biology, Genome Evolution, Biotechnological Issues and Research Including Applied Perspectives in Artemisia (Asteraceae). , 349-419.
CrossRef155
Carrie A Morris, Stephan Duparc, Isabelle Borghini-Fuhrer, Donald Jung, Chang-Sik Shin, Lawrence Fleckenstein. (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malaria Journal 10:1, 263
CrossRef156
P. Harris, S. Price, S. Senthuran, J. Cochupanachimootil, R. Norton. (2011) Automated erythrocytapheresis for severe falciparum malaria. Internal Medicine Journal 41:1a, 60-63
CrossRef157
Lindsay J Mangham, Bonnie Cundill, Ogochukwu Ezeoke, Emmanuel Nwala, Benjamin SC Uzochukwu, Virginia Wiseman, Obinna Onwujekwe. (2011) Treatment of uncomplicated malaria at public health facilities and medicine retailers in south-eastern Nigeria. Malaria Journal 10:1, 155
CrossRef158
Humphrey D Mazigo, Wilfred Meza, Emanuella E Ambrose, Benson R Kidenya, Eliningaya J Kweka. (2011) Confirmed malaria cases among children under five with fever and history of fever in rural western Tanzania. BMC Research Notes 4:1, 359
CrossRef159
Charles J. Woodrow, Leyla Y. Bustamante. (2011) Mechanisms of artemisinin action and resistance: wider focus is needed. Trends in Parasitology 27:1, 2-3
CrossRef160
Jimee Hwang, Bereket H Alemayehu, David Hoos, Zenebe Melaku, Samuel G Tekleyohannes, Takele Teshi, Sintayehu G Birhanu, Leykun Demeke, Kedir Gobena, Moges Kassa, Daddi Jima, Richard Reithinger, Henry Nettey, Michael Green, Joseph L Malone, S Patrick Kachur, Scott Filler. (2011) In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Malaria Journal 10:1, 209
CrossRef161
Jakob P Cramer, Rogelio López-Vélez, Gerd D Burchard, Martin P Grobusch, Peter J de Vries. (2011) Treatment of imported severe malaria with artesunate instead of quinine - more evidence needed?. Malaria Journal 10:1, 256
CrossRef162
Bethel Kwansa-Bentum, Irene Ayi, Takashi Suzuki, Joseph Otchere, Takashi Kumagai, William K Anyan, Joseph HN Osei, Hiroko Asahi, Michael F Ofori, Nobuaki Akao, Michael D Wilson, Daniel A Boakye, Nobuo Ohta. (2011) Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro. Malaria Journal 10:1, 187
CrossRef163
Min Xu, Kathy T. Andrews, Geoff W. Birrell, Truc Linh Tran, David Camp, Rohan A. Davis, Ronald J. Quinn. (2011) Psammaplysin H, a new antimalarial bromotyrosine alkaloid from a marine sponge of the genus Pseudoceratina. Bioorganic & Medicinal Chemistry Letters 21:2, 846-848
CrossRef164
Francesc Marti, James Chadwick, Richard K. Amewu, Hollie Burrell-Saward, Abhishek Srivastava, Stephen A. Ward, Raman Sharma, Neil Berry, Paul M. O'Neill. (2011) Second generation analogues of RKA182: synthetic tetraoxanes with outstanding in vitro and in vivo antimalarial activities. MedChemComm 2:7, 661
CrossRef165
Kate B Gardner, Ipsita Sinha, Leyla Y Bustamante, Nicholas PJ Day, Nicholas J White, Charles J Woodrow. (2011) Protein-based signatures of functional evolution in Plasmodium falciparum. BMC Evolutionary Biology 11:1, 257
CrossRef166
Anne EP Frosch, Meera Venkatesan, Miriam K Laufer. (2011) Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malaria Journal 10:1, 116
CrossRef167
Arya Ajay, Vandana Singh, Shubhra Singh, Swaroop Pandey, Sarika Gunjan, Divya Dubey, Sudhir Kumar Sinha, Bhupendra N. Singh, Vinita Chaturvedi, Renu Tripathi, Ravishankar Ramchandran, Rama P. Tripathi. (2010) Synthesis and bio-evaluation of alkylaminoaryl phenyl cyclopropyl methanones as antitubercular and antimalarial agents. Bioorganic & Medicinal Chemistry 18:23, 8289-8301
CrossRef168
Eric M. Guantai, Kanyile Ncokazi, Timothy J. Egan, Jiri Gut, Philip J. Rosenthal, Peter J. Smith, Kelly Chibale. (2010) Design, synthesis and in vitro antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds. Bioorganic & Medicinal Chemistry 18:23, 8243-8256
CrossRef169
Adoke Yeka, Jamal C Harris. (2010) Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies. Current Opinion in Pediatrics 22:6, 798-803
CrossRef170
Shigeyuki Kano. (2010) Artemisinin-based combination therapies and their introduction in Japan. Journal of Infection and Chemotherapy 16:6, 375-382
CrossRef171
Ingrid B Müller, John E Hyde. (2010) Antimalarial drugs: modes of action and mechanisms of parasite resistance. Future Microbiology 5:12, 1857-1873
CrossRef172
Nicholas J White. (2010) Artemisinin resistance—the clock is ticking. The Lancet 376:9758, 2051-2052
CrossRef173
Richard GA Feachem, Allison A Phillips, Jimee Hwang, Chris Cotter, Benjamin Wielgosz, Brian M Greenwood, Oliver Sabot, Mario Henry Rodriguez, Rabindra R Abeyasinghe, Tedros Adhanom Ghebreyesus, Robert W Snow. (2010) Shrinking the malaria map: progress and prospects. The Lancet 376:9752, 1566-1578
CrossRef174
Rakesh Kumar, Dinesh Mohanakrishnan, Abhishek Sharma, Naveen Kumar Kaushik, Kalpana Kalia, Arun Kumar Sinha, Dinkar Sahal. (2010) Reinvestigation of structure–activity relationship of methoxylated chalcones as antimalarials: Synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone. European Journal of Medicinal Chemistry 45:11, 5292-5301
CrossRef175
Sanjeev Krishna, Serena Pulcini, Farrah Fatih, Henry Staines. (2010) Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. Trends in Parasitology 26:11, 517-523
CrossRef176
Nuno P. Mira, Miguel Cacho Teixeira, Isabel Sá-Correia. (2010) Adaptive Response and Tolerance to Weak Acids in Saccharomyces cerevisiae : A Genome-Wide View. OMICS: A Journal of Integrative Biology 14:5, 525-540
CrossRef177
Abdirahman Abdi, Sylvain Eschenlauer, Luc Reininger, Christian Doerig. (2010) SAM domain-dependent activity of PfTKL3, an essential tyrosine kinase-like kinase of the human malaria parasite Plasmodium falciparum. Cellular and Molecular Life Sciences 67:19, 3355-3369
CrossRef178
Martin Peter Grobusch, Michèle van Vugt. (2010) Malaria therapy: where do we stand, what next?. Future Microbiology 5:10, 1447-1449
CrossRef179
Danny A Milner. (2010) Rethinking cerebral malaria pathology. Current Opinion in Infectious Diseases 23:5, 456-463
CrossRef180
J.-F. Pays. (2010) Une moustiquaire pour tous en l’an 2010. Bulletin de la Société de pathologie exotique 103:4, 223-229
CrossRef181
Timothy ME Davis, Ivo Mueller, Stephen J Rogerson. (2010) Prevention and treatment of malaria in pregnancy. Future Microbiology 5:10, 1599-1613
CrossRef182
M. Rottmann, C. McNamara, B. K. S. Yeung, M. C. S. Lee, B. Zou, B. Russell, P. Seitz, D. M. Plouffe, N. V. Dharia, J. Tan, S. B. Cohen, K. R. Spencer, G. E. Gonzalez-Paez, S. B. Lakshminarayana, A. Goh, R. Suwanarusk, T. Jegla, E. K. Schmitt, H.-P. Beck, R. Brun, F. Nosten, L. Renia, V. Dartois, T. H. Keller, D. A. Fidock, E. A. Winzeler, T. T. Diagana. (2010) Spiroindolones, a Potent Compound Class for the Treatment of Malaria. Science 329:5996, 1175-1180
CrossRef183
T. N. C. Wells. (2010) Is the Tide Turning for New Malaria Medicines?. Science 329:5996, 1153-1154
CrossRef184
Jan B. Koenderink, Reginald A. Kavishe, Sanna R. Rijpma, Frans G.M. Russel. (2010) The ABCs of multidrug resistance in malaria. Trends in Parasitology 26:9, 440-446
CrossRef185
Inbarani Naidoo, Cally Roper. (2010) Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. Trends in Parasitology 26:9, 447-456
CrossRef186
Hai-Yong Hua, You-Sheng Liang, Yan Zhang, Ji-Fu Wei, Hong-Xiong Guo. (2010) The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China. Parasitology Research 107:4, 873-878
CrossRef187
T. J. C. Anderson, J. T. Williams, S. Nair, D. Sudimack, M. Barends, A. Jaidee, R. N. Price, F. Nosten. (2010) Inferred relatedness and heritability in malaria parasites. Proceedings of the Royal Society B: Biological Sciences 277:1693, 2531-2540
CrossRef188
Paul M. O'Neill, Richard K. Amewu, Gemma L. Nixon, Fatima Bousejra ElGarah, Mathirut Mungthin, James Chadwick, Alison E. Shone, Livia Vivas, Hollie Lander, Victoria Barton, Sant Muangnoicharoen, Patrick G. Bray, Jill Davies, B. Kevin Park, Sergio Wittlin, Reto Brun, Michael Preschel, Kesheng Zhang, Stephen A. Ward. (2010) Identification of a 1,2,4,5-Tetraoxane Antimalarial Drug-Development Candidate (RKA 182) with Superior Properties to the Semisynthetic Artemisinins. Angewandte Chemie 122:33, 5829-5833
CrossRef189
Paul M. O'Neill, Richard K. Amewu, Gemma L. Nixon, Fatima Bousejra ElGarah, Mathirut Mungthin, James Chadwick, Alison E. Shone, Livia Vivas, Hollie Lander, Victoria Barton, Sant Muangnoicharoen, Patrick G. Bray, Jill Davies, B. Kevin Park, Sergio Wittlin, Reto Brun, Michael Preschel, Kesheng Zhang, Stephen A. Ward. (2010) Identification of a 1,2,4,5-Tetraoxane Antimalarial Drug-Development Candidate (RKA 182) with Superior Properties to the Semisynthetic Artemisinins. Angewandte Chemie International Edition 49:33, 5693-5697
CrossRef190
Edgar Deu, Melissa J. Leyva, Victoria E. Albrow, Mark J. Rice, Jonathan A. Ellman, Matthew Bogyo. (2010) Functional Studies of Plasmodium falciparum Dipeptidyl Aminopeptidase I Using Small Molecule Inhibitors and Active Site Probes. Chemistry & Biology 17:8, 808-819
CrossRef191
Phurpa Wangchuk, John B. Bremner, Samten, Brian W. Skelton, Allan H. White, Roonglawan Rattanajak, Sumalee Kamchonwongpaisan. (2010) Antiplasmodial activity of atisinium chloride from the Bhutanese medicinal plant, Aconitum orochryseum. Journal of Ethnopharmacology 130:3, 559-562
CrossRef192
Gundula Min-Oo, Kodjo Ayi, Silayuv E. Bongfen, Mifong Tam, Irena Radovanovic, Susan Gauthier, Helton Santiago, Antonio Gigliotti Rothfuchs, Ester Roffê, Alan Sher, Alaka Mullick, Anny Fortin, Mary M. Stevenson, Kevin C. Kain, Philippe Gros. (2010) Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium. Experimental Parasitology 125:4, 315-324
CrossRef193
Lorena Carneiro Albernaz, José Elias de Paula, Gustavo Adolfo Sierra Romero, Maria do Rosário Rodrigues Silva, Phillipe Grellier, Lengo Mambu, Laila Salmen Espindola. (2010) Investigation of plant extracts in traditional medicine of the Brazilian Cerrado against protozoans and yeasts. Journal of Ethnopharmacology 131:1, 116-121
CrossRef194
Takuya Miura, Koushi Hidaka, Tsuyoshi Uemura, Keisuke Kashimoto, Yuto Hori, Yuko Kawasaki, Adam J. Ruben, Ernesto Freire, Tooru Kimura, Yoshiaki Kiso. (2010) Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorganic & Medicinal Chemistry Letters 20:16, 4836-4839
CrossRef195
Cecilia P. Sanchez, Anurag Dave, Wilfred D. Stein, Michael Lanzer. (2010) Transporters as mediators of drug resistance in Plasmodium falciparum. International Journal for Parasitology 40:10, 1109-1118
CrossRef196
Sergio A. Caldarelli, Jean-Frédéric Duckert, Sharon Wein, Michèle Calas, Christian Périgaud, Henri Vial, Suzanne Peyrottes. (2010) Synthesis and Evaluation of Bis-Thiazolium Salts as Potential Antimalarial Drugs. ChemMedChem 5:7, 1102-1109
CrossRef197
Bhavna Gupta, Gauri Awasthi, Aparup Das. (2010) Malaria parasite genome scan: insights into antimalarial resistance. Parasitology Research 107:2, 495-499
CrossRef198
Ushma Mehta, Elizabeth Allen, Karen I Barnes. (2010) Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria. Expert Review of Clinical Pharmacology 3:4, 509-525
CrossRef199
Xianming Deng, Advait Nagle, Tao Wu, Tomoyo Sakata, Kerstin Henson, Zhong Chen, Kelli Kuhen, David Plouffe, Elizabeth Winzeler, Francisco Adrian, Tove Tuntland, Jonathan Chang, Susan Simerson, Steven Howard, Jared Ek, John Isbell, David C. Tully, Arnab K. Chatterjee, Nathanael S. Gray. (2010) Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. Bioorganic & Medicinal Chemistry Letters 20:14, 4027-4031
CrossRef200
Takafumi Tsuboi, Satoru Takeo, Thangavelu U. Arumugam, Hitoshi Otsuki, Motomi Torii. (2010) The wheat germ cell-free protein synthesis system: A key tool for novel malaria vaccine candidate discovery. Acta Tropica 114:3, 171-176
CrossRef201
Henry M. Staines, Elvira T. Derbyshire, Ksenija Slavic, Amanda Tattersall, Henri Vial, Sanjeev Krishna. (2010) Exploiting the therapeutic potential of Plasmodium falciparum solute transporters. Trends in Parasitology 26:6, 284-296
CrossRef202
W. Armand Guiguemde, Anang A. Shelat, David Bouck, Sandra Duffy, Gregory J. Crowther, Paul H. Davis, David C. Smithson, Michele Connelly, Julie Clark, Fangyi Zhu, María B. Jiménez-Díaz, María S. Martinez, Emily B. Wilson, Abhai K. Tripathi, Jiri Gut, Elizabeth R. Sharlow, Ian Bathurst, Farah El Mazouni, Joseph W. Fowble, Isaac Forquer, Paula L. McGinley, Steve Castro, Iñigo Angulo-Barturen, Santiago Ferrer, Philip J. Rosenthal, Joseph L. DeRisi, David J. Sullivan, John S. Lazo, David S. Roos, Michael K. Riscoe, Margaret A. Phillips, Pradipsinh K. Rathod, Wesley C. Van Voorhis, Vicky M. Avery, R. Kiplin Guy. (2010) Chemical genetics of Plasmodium falciparum. Nature 465:7296, 311-315
CrossRef203
David A. Fidock. (2010) Drug discovery: Priming the antimalarial pipeline. Nature 465:7296, 297-298
CrossRef204
Jessica T. Lin, Jonathan J. Juliano, Chansuda Wongsrichanalai. (2010) Drug-Resistant Malaria: The Era of ACT. Current Infectious Disease Reports 12:3, 165-173
CrossRef205
Michelle S Hsiang, Rabindra Abeyasinghe, Maxine Whittaker, Richard GA Feachem. (2010) Malaria elimination in Asia–Pacific: an under-told story. The Lancet 375:9726, 1586-1587
CrossRef206
Carol Hopkins Sibley, Philippe J. Guerin, Pascal Ringwald. (2010) Monitoring antimalarial resistance: launching a cooperative effort. Trends in Parasitology 26:5, 221-224
CrossRef207
Roly D Gosling, Matthew E Cairns, R Matthew Chico, Daniel Chandramohan. (2010) Intermittent preventive treatment against malaria: an update. Expert Review of Anti-infective Therapy 8:5, 589-606
CrossRef208
Nithya Gogtay, Felicity Brand, Piero Olliaro, David Sinclair, David Sinclair. 2010. Artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapses. .
CrossRef209
Stephen P Kachur, John R MacArthur, Laurence Slutsker. (2010) A call to action: addressing the challenge of artemisinin-resistant malaria. Expert Review of Anti-infective Therapy 8:4, 365-366
CrossRef210
Rishabh Jain, Rositsa Jordanova, Ingrid B. Müller, Carsten Wrenger, Matthew R. Groves. (2010) Purification, crystallization and preliminary X-ray analysis of the aspartate aminotransferase of Plasmodium falciparum. Acta Crystallographica Section F Structural Biology and Crystallization Communications 66:4, 409-412
CrossRef211
Suresh G. Shelat, Jason P. Lott, Matthew S. Braga. (2010) Considerations on the use of adjunct red blood cell exchange transfusion in the treatment of severe Plasmodium falciparum malaria. Transfusion 50:4, 875-880
CrossRef212
Perry J.J. van Genderen, Dennis A. Hesselink, Jacob M. Bezemer, Pieter J. Wismans, David Overbosch. (2010) Efficacy and safety of exchange transfusion as an adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10-year single-center experience with a standardized treatment protocol. Transfusion 50:4, 787-794
CrossRef213
Arjen M. Dondorp, Shunmay Yeung, Lisa White, Chea Nguon, Nicholas P.J. Day, Duong Socheat, Lorenz von Seidlein. (2010) Artemisinin resistance: current status and scenarios for containment. Nature Reviews Microbiology
CrossRef214
Jonathan J. Juliano, Nahla Gadalla, Colin J. Sutherland, Steven R. Meshnick. (2010) The perils of PCR: can we accurately ‘correct’ antimalarial trials?. Trends in Parasitology 26:3, 119-124
CrossRef215
A. Nzila, L. Mwai. (2010) In vitro selection of Plasmodium falciparum drug-resistant parasite lines. Journal of Antimicrobial Chemotherapy 65:3, 390-398
CrossRef216
Alexis Nzila, John Okombo, Ruy Perez Becker, Roma Chilengi, Trudie Lang, Tim Niehues. (2010) Anticancer agents against malaria: time to revisit?. Trends in Parasitology 26:3, 125-129
CrossRef217
Christian Doerig, Abdirahman Abdi, Nicholas Bland, Sylvain Eschenlauer, Dominique Dorin-Semblat, Clare Fennell, Jean Halbert, Zoe Holland, Marie-Paule Nivez, Jean-Philippe Semblat, Audrey Sicard, Luc Reininger. (2010) Malaria: Targeting parasite and host cell kinomes. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1804:3, 604-612
CrossRef218
Ksenija Slavic, Ursula Straschil, Luc Reininger, Christian Doerig, Christophe Morin, Rita Tewari, Sanjeev Krishna. (2010) Life cycle studies of the hexose transporter of Plasmodium species and genetic validation of their essentiality. Molecular Microbiology 75:6, 1402-1413
CrossRef219
Jianbing Mu, Rachel A Myers, Hongying Jiang, Shengfa Liu, Stacy Ricklefs, Michael Waisberg, Kesinee Chotivanich, Polrat Wilairatana, Srivicha Krudsood, Nicholas J White, Rachanee Udomsangpetch, Liwang Cui, May Ho, Fengzhen Ou, Haibo Li, Jianping Song, Guoqiao Li, Xinhua Wang, Suon Seila, Sreng Sokunthea, Duong Socheat, Daniel E Sturdevant, Stephen F Porcella, Rick M Fairhurst, Thomas E Wellems, Philip Awadalla, Xin-zhuan Su. (2010) Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nature Genetics 42:3, 268-271
CrossRef220
Johan van Griensven, Manica Balasegaram, Filip Meheus, Jorge Alvar, Lutgarde Lynen, Marleen Boelaert. (2010) Combination therapy for visceral leishmaniasis. The Lancet Infectious Diseases 10:3, 184-194
CrossRef221
Marielle K. Bouyou-Akotet, Michael Ramharter, Edgard Brice Ngoungou, Modeste Mabika Mamfoumbi, Mireille Pemba Mihindou, Michel A. Missinou, Florian Kurth, Sabine Bélard, Selidji T. Agnandji, Saadou Issifou, János L. Heidecker, Sonja Trapp, Peter G. Kremsner, Maryvonne Kombila. (2010) Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wiener klinische Wochenschrift 122:5-6, 173-178
CrossRef222
I. A. Graham, K. Besser, S. Blumer, C. A. Branigan, T. Czechowski, L. Elias, I. Guterman, D. Harvey, P. G. Isaac, A. M. Khan, T. R. Larson, Y. Li, T. Pawson, T. Penfield, A. M. Rae, D. A. Rathbone, S. Reid, J. Ross, M. F. Smallwood, V. Segura, T. Townsend, D. Vyas, T. Winzer, D. Bowles. (2010) The Genetic Map of Artemisia annua L. Identifies Loci Affecting Yield of the Antimalarial Drug Artemisinin. Science 327:5963, 328-331
CrossRef223
Reik Löser, Jiri Gut, Philip J. Rosenthal, Maxim Frizler, Michael Gütschow, Katherine T. Andrews. (2010) Antimalarial activity of azadipeptide nitriles. Bioorganic & Medicinal Chemistry Letters 20:1, 252-255
CrossRef224
Marian Warsame, Peter Olumese, Kamini Mendis. (2010) Role of medicines in malaria control and elimination. Drug Development Researchn/a-n/a
CrossRef225
A. Enayati, J. Hemingway. (2010) Malaria Management: Past, Present, and Future. Annual Review of Entomology 55:1, 569-591
CrossRef226
Jürgen FJ Kun, Jürgen May, Harald Noedl. (2010) Surveillance of malaria drug resistance: improvement needed?. Therapy 7:1, 3-6
CrossRef227
Harparkash Kaur, Michael D Green, Dana M Hostetler, Facundo M Fernández, Paul N Newton. (2010) Antimalarial drug quality: methods to detect suspect drugs. Therapy 7:1, 49-57
CrossRef228
José Antonio Pérez-Molina, Marta Díaz-Menéndez, Ana Pérez-Ayala, Federico Ferrere, Begoña Monje, Francesca Norman, Rogelio López-Vélez. (2010) Tratamiento de las enfermedades causadas por parásitos. Enfermedades Infecciosas y Microbiología Clínica 28:1, 44-59
CrossRef229
Richard T. Eastman, David A. Fidock. (2009) Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Reviews Microbiology
CrossRef230
Philippe J Guerin, Sarah J Bates, Carol H Sibley. (2009) Global resistance surveillance: ensuring antimalarial efficacy in the future. Current Opinion in Infectious Diseases 22:6, 593-600
CrossRef231
Patricia Schlagenhauf, Eskild Petersen. (2009) Antimalaria drug resistance: the mono–combi–counterfeit triangle. Expert Review of Anti-infective Therapy 7:9, 1039-1042
CrossRef232
Timothy N. C. Wells, Pedro L. Alonso, Winston E. Gutteridge. (2009) New medicines to improve control and contribute to the eradication of malaria. Nature Reviews Drug Discovery 8:11, 879-891
CrossRef233
(2009) Artemisinin Resistance in Plasmodium falciparum Malaria. New England Journal of Medicine 361:18, 1807-1808
Full Text234
Roswitha Harrer. (2009) Neues vom Malaria-Erreger. Chemie in unserer Zeit 43:5, 266-266
CrossRef235
Wen Kilama, Francine Ntoumi. (2009) Malaria: a research agenda for the eradication era. The Lancet 374:9700, 1480-1482
CrossRef236
Campbell, Carlos C., . (2009) Malaria Control — Addressing Challenges to Ambitious Goals. New England Journal of Medicine 361:5, 522-523
Full Text237
Katharine Sanderson. (2009) Malaria becoming more drug resistant. Nature
CrossRef238
Richard J. Maude, Charles J. Woodrow, Lisa J. White. (2009) Artemisinin antimalarials: preserving the âmagic bulletâ. Drug Development Researchn/a-n/a
CrossRef
- Letters
